Komori
Other Disclosures4572Carna Biosciences,Inc.Pharmaceuticals

Supplementary Information on the Presentation at the European Hematology Association (EHA2026): Interim Results from the docirbrutinib (AS-1763) Phase 1b Trial

Interim results were announced from the Phase 1b trial of docirbrutinib (AS-1763), with patient enrollment expanded to 58. As safety was maintained and responses were confirmed in CLL/SLL, MCL and WM, a dose of 400 mg twice daily was selected as the provisional recommended dose for the Phase 2 trial, and enrollment of additional patients will proceed.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
58
Number of enrolled patients
Wording
Conditional
How definitive the wording is.

Announced details

docirbrutinib (AS-1763)
Applicable field (uses covered by this announcement)

Treatment of B-cell malignancies and hematologic cancers, including CLL/SLL, MCL, WM, MZL and FL

What the company reported numerically
Quantitative Effects

Grade 3 or higher treatment-related adverse events: 10%; overall response rate in CLL/SLL: 57%, including 73% in the 400 mg BID group (8/11 patients); overall response rate in MCL: 100% (7 patients); overall response rate and major response rate in WM: 100% (4 patients)

Usage history

58 patients enrolled in the Phase 1b trial (as of 8 May 2026); 28 patients evaluable for efficacy in CLL/SLL and 23 efficacy-evaluable patients with NHL

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Data presented at the European Hematology Association (EHA2026); Mato AR et al., Haematologica. 2018;103(5):874-879, cited for the safety comparison

Announced details
ItemDetails
Names of Products / Services Covereddocirbrutinib (AS-1763)
Applicable areaTreatment of B-cell malignancies and hematologic cancers, including CLL/SLL, MCL, WM, MZL and FL
Quantitative EffectsGrade 3 or higher treatment-related adverse events: 10%; overall response rate in CLL/SLL: 57%, including 73% in the 400 mg BID group (8/11 patients); overall response rate in MCL: 100% (7 patients); overall response rate and major response rate in WM: 100% (4 patients)
Usage history58 patients enrolled in the Phase 1b trial (as of 8 May 2026); 28 patients evaluable for efficacy in CLL/SLL and 23 efficacy-evaluable patients with NHL
SourceData presented at the European Hematology Association (EHA2026); Mato AR et al., Haematologica. 2018;103(5):874-879, cited for the safety comparison
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To obtain more reliable data and validate efficacy, as favorable safety, tolerability and efficacy were consistently confirmed even after expanding the number of cases.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Information on the Presentation at the European Hematology Association (EHA2026): Interim Results from the docirbrutinib (AS-1763) Phase 1b Trial | Carna Biosciences,Inc. (4572) timely disclosure | Komori